When was Kronos Bio founded?

Kronos Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Kronos Bio located?

Kronos Bio is headquartered in San Mateo, United States. It is registered at 1300 So. El Camino Real Suite 400 San Mateo, CA 94402.

How many employees does Kronos Bio have?

As of Feb 24, 2025, the latest employee count at Kronos Bio is 52.

Is Kronos Bio a funded company?

Kronos Bio is a funded company, having raised a total of $271M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 23, 2018.

How much is Kronos Bio worth?

The last known valuation of Kronos Bio was $***** as of Oct 05, 2020.

When was the latest funding round of Kronos Bio?

Kronos Bio's latest funding was a $***** Series B round on Aug 24, 2020, with participation from 13 investors.

Where does Kronos Bio rank among its competitors?

Kronos Bio ranks 232nd amongst 3381 active competitors, of which 1135 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Kronos Bio?

Kronos Bio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Kronos Bio - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of small molecule-based therapeutics for cancer treatment. The company has developed small molecules that bind or interfere with the target protein activity directly, disrupt protein-protein complexes, or affect nearest neighbor proteins that may indirectly modulate target activity.

Website: kronosbio.com
Social
Email ID: *****@kronosbio.com
Registered Address: 1300 So. El Camino Real Suite 400 San Mateo, CA 94402

Key Metrics

Founded Year

2017

Location

San Mateo, United States

Stage

Acquired

Total Funding

$271M in 3 rounds

Latest Funding Round

Series B, Aug 24, 2020, $*****

Last Known Valuation

$***** as on Oct 05, 2020

Investors

Omega Funds & 19 more

Ranked

232^nd among 3381 active competitors

Employee Count

52 as on Feb 24, 2025

Similar Companies

Jazz Pharmaceuticals & 3051 more

Exit Details

Acquired by Concentra Biosciences (May 01, 2025)

View Kronos Bio's full profile

Kronos Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Kronos Bio, Inc. CIN: 82-1895605 , United States, Active	Jun 01, 2017	-	97 (As on Dec 31, 2022)	-

Kronos Bio got acquired by Concentra Biosciences on May 01, 2025.

Click here to take a look at Kronos Bio's acquisition in detail

Kronos Bio has raised a total funding of $271M over 3 rounds. Its first funding round was on May 23, 2018. Its latest funding round was a Series B round on Aug 24, 2020 for $*****. 13 investors participated in its latest round. Kronos Bio has 17 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of Kronos Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 24, 2020	5706247	Series B	8633156	8178797	2307097	1878106
Jul 13, 2019	2075177	Series A	2212297	2834836	8537833	Google Ventures & 4 more
May 23, 2018	7709148	Seed	2006994	4019859	Omega Funds & 2 more	Two River & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Kronos Bio's funding rounds and investors

Kronos Bio's employee count trend

Kronos Bio has 52 employees as of Feb 25. Here is Kronos Bio's employee count trend over the years:

Uncover Kronos Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kronos Bio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Kronos Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
232nd	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Perceptive Advisors, Fidelity Investments ... & 18 others	58/100